Condition
Lou Gehrig Disease
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Unknown2
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06315608Phase 2Not Yet Recruiting
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
NCT05725759Unknown
Rehabilitation in SOD1 ALS Treated With Tofersen
NCT03868345Completed
Speech Analysis in ALS Patients
NCT03520517Phase 1Completed
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
NCT03537807Unknown
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
Showing all 5 trials